$SCPX
Scorpius Holdings, Inc.

2023 Q2 Form 10-Q Financial Statement

#000155837023009863 Filed on May 15, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $657.8K $765.9K
YoY Change 1190.24% 260.56%
Cost Of Revenue $383.7K $611.7K
YoY Change
Gross Profit $274.1K $154.2K
YoY Change
Gross Profit Margin 41.67% 20.13%
Selling, General & Admin $7.393M $6.821M
YoY Change 54.33% 80.6%
% of Gross Profit 2697.39% 4424.33%
Research & Development $5.733M $6.996M
YoY Change 21.29% 77.86%
% of Gross Profit 2091.66% 4538.04%
Depreciation & Amortization $1.100M $1.426M
YoY Change 604.15% 588.49%
% of Gross Profit 401.33% 924.95%
Operating Expenses $5.733M $6.996M
YoY Change -41.29% -9.01%
Operating Profit -$14.32M -$13.04M
YoY Change 47.39% 74.35%
Interest Expense -$217.0K $140.4K
YoY Change -48.13% -119.82%
% of Operating Profit
Other Income/Expense, Net -$217.0K $140.4K
YoY Change -60.6% -119.68%
Pretax Income -$14.53M -$12.90M
YoY Change 41.59% 57.45%
Income Tax -$600.0K $0.00
% Of Pretax Income
Net Earnings -$13.89M -$12.78M
YoY Change 36.77% 57.44%
Net Earnings / Revenue -2111.96% -1669.23%
Basic Earnings Per Share -$0.53 -$0.49
Diluted Earnings Per Share -$0.53 -$0.49
COMMON SHARES
Basic Shares Outstanding 26.05M 26.05M
Diluted Shares Outstanding 26.05M 25.97M

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $18.56M $28.64M
YoY Change -73.46% -65.95%
Cash & Equivalents $5.837M $7.827M
Short-Term Investments $12.73M $20.82M
Other Short-Term Assets $3.194M $3.493M
YoY Change 38.01% 47.68%
Inventory
Prepaid Expenses
Receivables $260.2K $98.04K
Other Receivables $600.9K $2.125M
Total Short-Term Assets $22.78M $34.36M
YoY Change -71.3% -60.32%
LONG-TERM ASSETS
Property, Plant & Equipment $19.11M $19.43M
YoY Change 263.84% 527.07%
Goodwill $3.873M $3.302M
YoY Change -23.57%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.692M $5.837M
YoY Change -92.87% -76.26%
Total Long-Term Assets $57.40M $57.16M
YoY Change 9.41% 106.44%
TOTAL ASSETS
Total Short-Term Assets $22.78M $34.36M
Total Long-Term Assets $57.40M $57.16M
Total Assets $80.18M $91.52M
YoY Change -39.19% -19.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.322M $3.051M
YoY Change -48.59% 36.92%
Accrued Expenses $3.479M $5.723M
YoY Change 26.81% 248.08%
Deferred Revenue $2.702M $2.039M
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $260.5K $225.0K
YoY Change 19.99% -7.86%
Total Short-Term Liabilities $15.34M $17.48M
YoY Change 1.38% 228.9%
LONG-TERM LIABILITIES
Long-Term Debt $7.729M $5.470M
YoY Change 4015.95% 2424.92%
Other Long-Term Liabilities $10.05M $8.229M
YoY Change 17697.57% 14840.65%
Total Long-Term Liabilities $17.78M $13.70M
YoY Change 31387.51% 24772.1%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.34M $17.48M
Total Long-Term Liabilities $17.78M $13.70M
Total Liabilities $33.12M $31.18M
YoY Change -9.19% 225.86%
SHAREHOLDERS EQUITY
Retained Earnings -$235.8M -$221.9M
YoY Change 28.15% 27.68%
Common Stock $5.210K $5.210K
YoY Change 1.76% 1.76%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $48.73M $61.94M
YoY Change
Total Liabilities & Shareholders Equity $80.18M $91.52M
YoY Change -39.19% -19.91%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income -$13.89M -$12.78M
YoY Change 36.77% 57.44%
Depreciation, Depletion And Amortization $1.100M $1.426M
YoY Change 604.15% 588.49%
Cash From Operating Activities -$8.209M -$13.79M
YoY Change -193.43% 35.05%
INVESTING ACTIVITIES
Capital Expenditures -$588.3K $1.625M
YoY Change -73.97% 48.97%
Acquisitions
YoY Change
Other Investing Activities $8.247M $15.11M
YoY Change -176.59% -15.53%
Cash From Investing Activities $8.836M $13.49M
YoY Change -167.82% -19.72%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -2.617M -298.5K
YoY Change 4576.79% 440.89%
NET CHANGE
Cash From Operating Activities -8.209M -13.79M
Cash From Investing Activities 8.836M 13.49M
Cash From Financing Activities -2.617M -298.5K
Net Change In Cash -1.990M -607.8K
YoY Change -53.7% -109.31%
FREE CASH FLOW
Cash From Operating Activities -$8.209M -$13.79M
Capital Expenditures -$588.3K $1.625M
Free Cash Flow -$7.620M -$15.42M
YoY Change -168.99% 36.39%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001476963
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25661488
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26049209
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-35994
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
NightHawk Biosciences, Inc.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-2844103
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
627 Davis Drive, Suite 300
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Morrisville
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NC
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
27560
CY2023Q1 dei City Area Code
CityAreaCode
919
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
240-7133
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock
CY2023Q1 dei Trading Symbol
TradingSymbol
NHWK
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NYSEAMER
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
26049209
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7826789
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8434554
CY2023Q1 us-gaap Short Term Investments
ShortTermInvestments
20815405
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
35837309
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
98035
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
81456
CY2023Q1 us-gaap Grants Receivable Current
GrantsReceivableCurrent
1524522
CY2022Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
1524522
CY2023Q1 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
600877
CY2022Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
600877
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3492621
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3575541
CY2023Q1 us-gaap Assets Current
AssetsCurrent
34358249
CY2022Q4 us-gaap Assets Current
AssetsCurrent
50054259
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
19430708
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20480375
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
8305625
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
8669375
CY2023Q1 us-gaap Goodwill
Goodwill
3301959
CY2022Q4 us-gaap Goodwill
Goodwill
3301959
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5729722
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6005147
CY2023Q1 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
14554625
CY2022Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
15329075
CY2023Q1 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
5557073
CY2022Q4 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
260011
CY2023Q1 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
279990
CY2022Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
296711
CY2023Q1 us-gaap Assets
Assets
91517951
CY2022Q4 us-gaap Assets
Assets
104396912
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
3050829
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4424053
CY2023Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2039486
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1585808
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
406694
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
490378
CY2023Q1 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
224983
CY2022Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
301048
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5723083
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4301922
CY2023Q1 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
6034114
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
6934114
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
17479189
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18037323
CY2023Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
32500
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
32500
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2996808
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3079887
CY2023Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
5470242
CY2022Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
5520034
CY2023Q1 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
5200000
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
5290500
CY2023Q1 us-gaap Liabilities
Liabilities
31178739
CY2022Q4 us-gaap Liabilities
Liabilities
31960244
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0002
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0002
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26049209
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25661488
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
5210
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
5126
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
283785089
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25593948
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25593948
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-12895136
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
283019456
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-221938306
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-209153659
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
83887
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
51924
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
61935880
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
73922847
CY2023Q1 us-gaap Minority Interest
MinorityInterest
-1596668
CY2022Q4 us-gaap Minority Interest
MinorityInterest
-1486179
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
60339212
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
72436668
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
91517951
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
104396912
CY2023Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
765900
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
212418
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
611740
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6995848
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3933347
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6820550
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3776623
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
363750
CY2023Q1 nhwk Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
-990500
CY2022Q1 nhwk Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
-21000
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
13801388
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
7688970
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-13035488
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7476552
CY2022Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-7779
CY2023Q1 us-gaap Interest Income Other
InterestIncomeOther
51030
CY2022Q1 us-gaap Interest Income Other
InterestIncomeOther
115568
CY2023Q1 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
89322
CY2022Q1 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-836593
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
140352
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-713246
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12895136
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8189798
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-12895136
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-8189798
CY2023Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-110489
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-69211
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-12784647
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-8120587
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25971143
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25971143
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-8189798
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
31963
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-55269
CY2023Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-12863173
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-8245067
CY2023Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-110489
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-69211
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12752684
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8175856
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
72436668
CY2023Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
765717
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
31963
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-12895136
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
60339212
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
112033571
CY2022Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
909984
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-55269
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-8189798
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
104698488
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-12895136
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-8189798
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1425904
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
207106
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
363750
CY2023Q1 nhwk Noncash Lease Expense
NoncashLeaseExpense
108660
CY2022Q1 nhwk Noncash Lease Expense
NoncashLeaseExpense
21536
CY2022Q1 nhwk Noncash Interest Expense
NoncashInterestExpense
6317
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
765717
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
909984
CY2022Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-7779
CY2023Q1 nhwk Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
-990500
CY2022Q1 nhwk Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
-21000
CY2023Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
89322
CY2022Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-907315
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
16938
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
33047
CY2022Q1 nhwk Increase Decrease In Grants Receivable
IncreaseDecreaseInGrantsReceivable
206163
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-82659
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-539003
CY2023Q1 nhwk Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-597046
CY2023Q1 nhwk Increase Decrease In Other Assets Miscellaneous Noncurrent
IncreaseDecreaseInOtherAssetsMiscellaneousNoncurrent
3698297
CY2022Q1 nhwk Increase Decrease In Other Assets Miscellaneous Noncurrent
IncreaseDecreaseInOtherAssetsMiscellaneousNoncurrent
4801687
CY2023Q1 nhwk Increase Decrease In Deposits Operating Activity
IncreaseDecreaseInDepositsOperatingActivity
16721
CY2022Q1 nhwk Increase Decrease In Deposits Operating Activity
IncreaseDecreaseInDepositsOperatingActivity
-2406
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1373185
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1303871
CY2023Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
453678
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1454412
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-849470
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
1550
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13794831
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10214668
CY2023Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
189218
CY2022Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
109806
CY2023Q1 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
15300444
CY2022Q1 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
17998995
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1624931
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1090748
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
13486295
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
16798441
CY2023Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
298523
CY2022Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
55191
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-298523
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-55191
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-706
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2254
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-607765
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
6530836
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8434554
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8053879
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7826789
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14584715
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
293172
CY2023Q1 nhwk Right Of Use Asset Obtained In Exchange For Operating Lease Liability Modifications
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilityModifications
-424379
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
768776
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-221900000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-12900000
CY2023Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
28600000
CY2023Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Estimates are used for, but not limited to, useful lives of fixed assets, contingent consideration, income taxes, valuation of warrant liabilities, and stock-based compensation. Actual results may differ from those estimates.</p>
CY2023Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2000000.0
CY2022Q1 nhwk Assets Transfer From Level1 To Level2 Transfers Amount1
AssetsTransferFromLevel1ToLevel2TransfersAmount1
0
CY2023Q1 nhwk Assets Transfer From Level1 To Level2 Transfers Amount1
AssetsTransferFromLevel1ToLevel2TransfersAmount1
0
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
9357
CY2023Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
0
CY2023Q1 nhwk Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
-1000000.0
CY2022Q1 nhwk Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
-20000.00
CY2023Q1 nhwk Prepaid Manufacturing Expense
PrepaidManufacturingExpense
2159067
CY2022Q4 nhwk Prepaid Manufacturing Expense
PrepaidManufacturingExpense
1849875
CY2023Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1100789
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1432242
CY2023Q1 us-gaap Prepaid Insurance
PrepaidInsurance
145349
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
227532
CY2023Q1 nhwk Prepaid Preclinical And Clinical Expenses
PrepaidPreclinicalAndClinicalExpenses
87416
CY2022Q4 nhwk Prepaid Preclinical And Clinical Expenses
PrepaidPreclinicalAndClinicalExpenses
65892
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3492621
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3575541
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
23468529
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
23442363
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4037821
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2961988
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
19430708
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20480375
CY2023Q1 us-gaap Depreciation
Depreciation
1100000
CY2022Q1 us-gaap Depreciation
Depreciation
200000
CY2022Q4 us-gaap Goodwill
Goodwill
3301959
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
8669375
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
363750
CY2023Q1 us-gaap Goodwill
Goodwill
3301959
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
8305625
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
2.32
CY2023Q1 nhwk Accrued Manufacturing Expenses
AccruedManufacturingExpenses
1669130
CY2022Q4 nhwk Accrued Manufacturing Expenses
AccruedManufacturingExpenses
594358
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1136634
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1176963
CY2023Q1 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1092558
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1092560
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
912825
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
438049
CY2023Q1 nhwk Accrued Clinical Trial Expense Current
AccruedClinicalTrialExpenseCurrent
861936
CY2022Q4 nhwk Accrued Clinical Trial Expense Current
AccruedClinicalTrialExpenseCurrent
959992
CY2023Q1 nhwk Accrued Franchise Tax
AccruedFranchiseTax
50000
CY2022Q4 nhwk Accrued Franchise Tax
AccruedFranchiseTax
40000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5723083
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4301922
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
800000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
900000
CY2022Q1 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
0
CY2023Q1 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.0192
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.0382
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0247
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0195
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y7M6D
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7036874
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.67
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
16842
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
45276
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
5.52
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
78549
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.27
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6913049
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.65
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y10M24D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3241344
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.73
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
18105
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y3M18D
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
4400000
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y2M12D
CY2023Q1 us-gaap Grants Receivable Current
GrantsReceivableCurrent
1500000
CY2022Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
1500000
CY2022 nhwk Process Development Revenue Recognized
ProcessDevelopmentRevenueRecognized
700000
CY2023Q1 nhwk Number Of Customers Revenue Derived From
NumberOfCustomersRevenueDerivedFrom
1
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023Q1 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
200000
CY2022Q4 nhwk Process Development Contract Liability
ProcessDevelopmentContractLiability
1618308
CY2023Q1 nhwk Process Development Contract Liability Reclassification To Revenue
ProcessDevelopmentContractLiabilityReclassificationToRevenue
665900
CY2023Q1 nhwk Process Development Contract Liability Net Change To Contract Balance
ProcessDevelopmentContractLiabilityNetChangeToContractBalance
1119578
CY2023Q1 nhwk Process Development Contract Liability
ProcessDevelopmentContractLiability
2071986
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-12895136
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-8189798
CY2023Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-110489
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-69211
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-12784647
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-8120587
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25971143
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25593948
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
CY2023Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
334541
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
125503
CY2023Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
350071
CY2022Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
62861
CY2023Q1 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
134443
CY2022Q1 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
6317
CY2023Q1 us-gaap Lease Cost
LeaseCost
484514
CY2022Q1 us-gaap Lease Cost
LeaseCost
69178
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y1M6D
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y7M6D
CY2023Q1 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P13Y3M18D
CY2022Q1 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P1Y10M24D
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0938
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0562
CY2023Q1 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0965
CY2022Q1 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0547
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
546658
CY2023Q1 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
509322
CY2023Q1 nhwk Lease Liability To Be Paid Remainder Of Fiscal Year
LeaseLiabilityToBePaidRemainderOfFiscalYear
1055980
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
618918
CY2023Q1 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
812383
CY2023Q1 nhwk Lease Liability To Be Paid Year One
LeaseLiabilityToBePaidYearOne
1431301
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
635180
CY2023Q1 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
715782
CY2023Q1 nhwk Lease Liability To Be Paid Year Two
LeaseLiabilityToBePaidYearTwo
1350962
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
575349
CY2023Q1 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
595309
CY2023Q1 nhwk Lease Liability To Be Paid Year Three
LeaseLiabilityToBePaidYearThree
1170658
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
592572
CY2023Q1 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
615269
CY2023Q1 nhwk Lease Liability To Be Paid Year Four
LeaseLiabilityToBePaidYearFour
1207841
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
610407
CY2023Q1 us-gaap Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
635827
CY2023Q1 nhwk Lease Liability To Be Paid Year Five
LeaseLiabilityToBePaidYearFive
1246234
CY2023Q1 nhwk Lessee Operating Lease Liability To Be Paid Year Six
LesseeOperatingLeaseLiabilityToBePaidYearSix
628723
CY2023Q1 nhwk Finance Lease Liability To Be Paid Year Six
FinanceLeaseLiabilityToBePaidYearSix
657002
CY2023Q1 nhwk Lease Liability To Be Paid Year Six
LeaseLiabilityToBePaidYearSix
1285725
CY2023Q1 nhwk Lessee Operating Lease Liability To Be Paid After Year Six
LesseeOperatingLeaseLiabilityToBePaidAfterYearSix
536932
CY2023Q1 nhwk Finance Lease Liability To Be Paid After Year Six
FinanceLeaseLiabilityToBePaidAfterYearSix
6423306
CY2023Q1 nhwk Lease Liability To Be Paid After Year Six
LeaseLiabilityToBePaidAfterYearSix
6960238
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
4744739
CY2023Q1 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
10964200
CY2023Q1 nhwk Lease Liability Payment Due
LeaseLiabilityPaymentDue
15708939
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1341237
CY2023Q1 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
5268975
CY2023Q1 nhwk Lease Liability Undiscounted Excess Amount
LeaseLiabilityUndiscountedExcessAmount
6610212
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
3403502
CY2023Q1 us-gaap Finance Lease Liability
FinanceLeaseLiability
5695225
CY2023Q1 nhwk Lease Liability
LeaseLiability
9098727

Files In Submission

Name View Source Status
0001558370-23-009863-index-headers.html Edgar Link pending
0001558370-23-009863-index.html Edgar Link pending
0001558370-23-009863.txt Edgar Link pending
0001558370-23-009863-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nhwk-20230331.xsd Edgar Link pending
nhwk-20230331x10q.htm Edgar Link pending
nhwk-20230331xex31d1.htm Edgar Link pending
nhwk-20230331xex31d2.htm Edgar Link pending
nhwk-20230331xex32d1.htm Edgar Link pending
nhwk-20230331xex32d2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
nhwk-20230331_cal.xml Edgar Link unprocessable
nhwk-20230331_def.xml Edgar Link unprocessable
nhwk-20230331_pre.xml Edgar Link unprocessable
nhwk-20230331x10q_htm.xml Edgar Link completed
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
nhwk-20230331_lab.xml Edgar Link unprocessable